台灣東洋藥品工業股份有限公司
東洋藥品工業股份有限公司（TTY Biopharm Company Limited）開發銷售醫藥與化學藥物。經營分為癌症、重症、保健及 CDMO 代工。提供癌症藥物（如 Lipo-Dox）、抗感染與麻醉藥物，及腸胃骨骼保健品。公司成立於 1960 年，總部位於台灣台北。
該股 RSI(6) 為 62.6，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日、60日、120日均線。KD 指標中性（K=72.9）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | +209 | 0 | +2 | +209 |
| 08-07 | +270 | 0 | +5 | +269 |
| 08-06 | -91 | 0 | +4 | -90 |
| 08-05 | -191 | -3 | +8 | -194 |
| 08-04 | +745 | -4 | 0 | +705 |
| 08-03 | +99 | +1 | +8 | +90 |
| 07-31 | -1,295 | +18 | +2 | -1,276 |
| 07-30 | +88 | -2 | +20 | +39 |
| 07-29 | -142 | 0 | +4 | -143 |
| 07-28 | +211 | -9 | +77 | +272 |
| 07-27 | +58 | 0 | 0 | +44 |
| 07-24 | +270 | 0 | 0 | +256 |
| 07-23 | +369 | +4 | +12 | +372 |
| 07-22 | -805 | -2 | +13 | -830 |
| 07-21 | +326 | 0 | 0 | +305 |
| 07-20 | +45 | 0 | 0 | +45 |
| 07-17 | +399 | 0 | +59 | +442 |
| 07-16 | +78 | 0 | 0 | +78 |
| 07-15 | +457 | +1 | +7 | +463 |
| 07-14 | +129 | 0 | +43 | +171 |
| 07-13 | +116 | 0 | +5 | +121 |
| 07-09 | +97 | -8 | 0 | +89 |
| 07-08 | -94 | 0 | +15 | -79 |
| 07-07 | +156 | 0 | +25 | +181 |
| 07-06 | +412 | 0 | 0 | +411 |
| 07-03 | +708 | 0 | +2 | +709 |
| 07-02 | -76 | 0 | 0 | -76 |
| 07-01 | -126 | +1,121 | +14 | +994 |
| 06-30 | -7 | -139 | 0 | -146 |
| 06-29 | +469 | 0 | +10 | +474 |
| 06-26 | +175 | -10 | 0 | +163 |
| 06-25 | +301 | -140 | +3 | +164 |
| 06-24 | +532 | -167 | 0 | +365 |
| 06-23 | +74 | -65 | +2 | +4 |
| 06-22 | -237 | -211 | +5 | -447 |
| 06-18 | +189 | -304 | +7 | -115 |
| 06-17 | +20 | -178 | 0 | -163 |
| 06-16 | -273 | 0 | +5 | -274 |
| 06-15 | +65 | -1 | +3 | +66 |
| 06-12 | -232 | -2 | 0 | -234 |
| 06-11 | -13 | 0 | +2 | -44 |
| 06-10 | +720 | -215 | 0 | +503 |
| 06-09 | -73 | -205 | 0 | -280 |
| 06-08 | +273 | 0 | +37 | +285 |
| 06-05 | +773 | 0 | +2 | +768 |
| 06-04 | +356 | 0 | 0 | +331 |
| 06-03 | -31 | 0 | +32 | -179 |
| 06-02 | +1,555 | -172 | +6 | +1,260 |
| 06-01 | +652 | 0 | +2 | +542 |
| 05-29 | -8 | -35 | +2 | -58 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 5.18 億 | -13.6% | +17.9% |
| 2026/03 | 6.00 億 | +66.8% | +5.8% |
| 2026/02 | 3.60 億 | -35.9% | -12.1% |
| 2026/01 | 5.61 億 | -12.5% | +16.2% |
| 2025/12 | 6.42 億 | +31.7% | +4.5% |
| 2025/11 | 4.87 億 | -8.6% | +7.0% |
| 2025/10 | 5.33 億 | -39.4% | -16.0% |
| 2025/09 | 8.79 億 | +92.1% | +45.1% |
| 2025/08 | 4.58 億 | -5.1% | +3.2% |
| 2025/07 | 4.83 億 | -9.8% | -0.2% |
| 2025/06 | 5.35 億 | -0.5% | +13.0% |
| 2025/05 | 5.38 億 | - | +21.1% |